Lung cancer is having a malignant tumor in the lungs especially in the cells lining air passages.
Primary tumor-related signs and symptoms are cough, dyspnea, hemoptysis, and chest discomfort.
Signs and symptoms due to intrathoracic spread may involve the nerves (hoarseness, dyspnea, muscle wasting of upper limb, Horner's syndrome), chest wall and pleura (chest pain, dyspnea) and vascular structures (facial swelling, dilated neck veins, cardiac tamponade) & viscera (dsyphagia).
The signs and symptoms due to metastatic spread are bone pain with or without pleuritic pain, neurologic symptoms, limb weakness, unsteady gait, cervical lymphadenopathy, and skin nodules.
Combining the monoclonal antibody targeting PD-L1 atezolizumab and the antiangiogenic biologic bevacizumab with a chemotherapy of carboplatin + paclitaxel (CP) for treating non-squamous metastatic non-small-cell lung cancer (NSCLC) leads to significant improvement in progression-free survival (PFS) compared with bevacizumab + CP as first-line treatment, according to the IMpower150* trial presented at the ESMO Immuno Oncology Congress 2017.
Adding the anti-HGF* antibody ficlatuzumab to the EGFR TKI** gefitinib shows promising antitumour activity and is well tolerated in Asian patients with advanced non-small-cell lung cancer (NSCLC), according to a phase Ib study.
Treatment with the PD-L1* inhibitor durvalumab after chemoradiotherapy significantly prolongs progression-free survival (PFS) by 11 months in patients with locally advanced, unresectable stage III non–small-cell lung cancer (NSCLC), with similar benefits in an Asian subset, according to the PACIFIC** study presented at ESMO Asia 2017 in Singapore.
Osimertinib further extends progression-free survival (PFS) over standard-of-care (SOC) first-line therapy in Asian patients with advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the phase III FLAURA* trial.
Indication and demand for genetic testing have increased in recent years, with tests becoming more readily available and affordable, says a leading oncologist at ESMO Asia 2017, highlighting that appreciation of ethical, social, and legal implications of testing and proper test interpretation are important for optimal patient management.
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Patients with limited-stage small-cell lung cancer (SCLC) have comparable overall survival (OS) regardless of whether they receive a once-daily or twice-daily concurrent chemoradiotherapy regimen, demonstrated results of the CONVERT* trial.
Using the PD-1* inhibitor nivolumab as first-line therapy for stage IV or recurrent non-small cell lung cancer (NSCLC) offers comparable survival as platinum-based chemotherapy, albeit with a better safety profile, according to the CheckMate 026** trial.
Extended preloading of varenicline for 6 weeks before the target quit day (TQD) safely improves the efficacy of the prescription medication in facilitating smoking cessation at 12 weeks and at 6 months, according to a study presented at the American Thoracic Society (ATS) 2019 International Conference, held at Dallas, Texas in the US.